Private: Gallery Post #1

27

Aug2019
PDCI and 3Sixty Public Affairs invites its industry clients, partners and colleagues to participate in a webinar on September 4, 2019 between 2:00pm to 3:00pm. This important session will cover the PMPRB price regulatory amendments and share insights on their implications for pharmaceutical market access. The session will provide an overview of ... Read More

19

Aug2019
The PMPRB has announced the 2020 meeting dates to the Human Drug Advisory Panel (HDAP)’s , releasing a total of four (4) dates, as per previous years. This corrected version of TargetPharma makes a distinction between the deadline for submitting the Product Monograph and the deadline for the Patentee's submission.... Read More

12

Aug2019
Each month the pCPA issues an update on the previous month’s negotiation activity. Below, you will find an overview of the new pCPA activity along with PDCI insights into recent developments for your interest. Summary of New pCPA Activity ... Read More

09

Aug2019
PMPRB and Health Canada held two technical briefings on the soon-to-be published final amendments to the Patented Medicines Regulations (PMR) on August 9th, 2019. This coincided with the pre-release of the final regulatory text and an updated Regulatory Impact Analysis Statement (RIAS). Publication in Canada Gazette II is expected August ... Read More

08

Aug2019
CADTH’s Pharmaceutical Reviews Updates are used to communicate new CDR and pCODR drug review processes updates to the public. PDCI has outlined below the key highlights from the most recent update. For more information on this review, please consult the CADTH’s website. CADTH has three new consultations ... Read More

08

Jul2019
Each month the pCPA issues an update on the previous month’s negotiation activity. Below you will find an overview of the new pCPA activity along with PDCI insights into recent developments for your interest. Summary of New pCPA Activity Since Last Update Category New File... Read More

19

Jun2019
Each month the pCPA issues an update on the previous month’s negotiation activity. In the summary below you will find an overview of the new pCPA activity along with PDCI insights into recent developments for your information. Summary of New pCPA Activity Since Last Update... Read More

18

Jun2019
Effective June 14, 2019, Mélanie Bourassa Forcier is Vice-Chairperson of the Patented Medicine Prices Review Board (PMPRB)    Professor Bourassa Forcier is an Associate Professor in the Faculty of Law at the Université de Sherbrooke, and directs the Law and Health Policy, and Law and Life Sciences programs. ... Read More

17

Jun2019
New “PROVISIONAL ALGORITHMS” at the Centre of Changes to Cancer Therapy Reviews  Effective July 1, 2019, process and operational changes will be made to integrate the functions of the Cancer Drug Implementation Advisory Committee (CDIAC) to CADTH and its pCODR process. Solicitation of stakeholder feedback began in March of this year.  The integration of CDIAC into the pCODR process is intended to further enhance transparency of cancer ... Read More

14

Jun2019
Mark down June 26th, 2019 in your calendars. It is now widely expected the patented medicines price regulations will be in Canada Gazette Part II (CGII), volume 151 No.13, which will be released on June 26th. Draft PMPRB Guidelines for consultation will likely be published immediately following CGII publication. Comments earlier this week from Federal Health Minister Petitpas-Taylor, appeared to confirm these expectations. When asked in an interview surrounding when changes to the ... Read More